ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mié, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Al cierre del primer trimestre de 2023
ROVI LOGRA UNOS INGRESOS DE 201,9 MILLONES DE EUROS EN EL PRIMER TRIMESTRE POSPANDEMIA
La...
15 min
10/05/2023
ROVI INICIA EL DESARROLLO CLÍNICO DE UNA NUEVA FORMULACIÓN TRIMESTRAL DE LETROZOL (LETROZOL LEBE)
El objetivo de la nueva...
7 min
25/04/2023
Madrid, 12 de abril de 2023
La Universidad Pontificia Comillas, en colaboración con Laboratorios Farmacéuticos ROVI, ha puesto en marcha...
3 min
12/04/2023
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.